8 studies found for:    19474385 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Withdrawn Photoacoustic Endoscopy in Endometrial Cancer
Conditions: Endometrial Cancer;   Benign Neoplasm of Body of Uterus
Interventions: Device: Photoacoustic endoprobe;   Procedure: Photoacoustic endoscopy
2 Recruiting A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers
Condition: Monoclonal B-Cell Lymphocytosis
Intervention:
3 Recruiting Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.
Condition: Metastatic Colorectal Cancer
Interventions: Procedure: Metastases resection;   Drug: Bevacizumab;   Drug: 5 FU (5Fluorouracile);   Drug: Oxaliplatine;   Drug: Irinotecan
4 Recruiting Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors
Condition: Metastatic Colorectal Cancer
Interventions: Procedure: Metastases Resection;   Drug: 5-Fluorouracile;   Drug: leucovorin L;   Drug: Oxaliplatin;   Drug: Irinotecan;   Drug: Cetuximab
5 Recruiting Cabozantinib for Advanced Urothelial Cancer
Conditions: Urethral Neoplasms;   Ureteral Neoplasms;   Urinary Bladder Neoplasms;   Kidney Neoplasms
Intervention: Drug: Cabozantinib
6 Completed Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
Conditions: Histologically or Cytologically Confirmed Pancreatic Ca;   Unresectable or Borderline Resectable Pancreatic Ca
Intervention: Drug: Gemcitabine
7 Recruiting Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer
Condition: Anal Cancer
Interventions: Drug: Tempol;   Drug: 5-Fluorouracil;   Drug: Mitomycin-C;   Procedure: Radiation Therapy
8 Active, not recruiting Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Condition: Non Small Cell Lung Carcinoma
Interventions: Drug: AZD6244;   Drug: Erlotinib;   Drug: AZD6244 + Erlotinib

Indicates status has not been verified in more than two years